Iovance Biotherapeutics
IOVA
236 hedge funds and large institutions have $1.69B invested in Iovance Biotherapeutics in 2023 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 87 increasing their positions, 70 reducing their positions, and 36 closing their positions.
170% more call options, than puts
Call options by funds: $55.3M | Put options by funds: $20.5M
74% more capital invested
Capital invested by funds: $970M → $1.69B (+$716M)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
33% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 36
24% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 70
4% more funds holding
Funds holding: 227 → 236 (+9)
4.99% less ownership
Funds ownership: 86.01% → 81.02% (-5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$11M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$7.39M |
| 3 |
Morgan Stanley
New York
|
+$6.45M |
| 4 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$5.51M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$5.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$36M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$12.1M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$8.64M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.43M |
| 5 |
Renaissance Technologies
New York
|
-$5.58M |
IOVA Hedge Fund Activity: Q4 2023 in Review
236 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2023, worth a combined $1.69B — up 74% from $970M a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new IOVA positions and 36 closed out — a net gain of 12 holders — while 87 added to existing stakes and 70 trimmed.
The largest buyer was Palo Alto Investors, opening a new position worth an estimated $11M. The largest seller was Millennium Management, cutting an estimated $36M.
- 236 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2023, up from 227 in Q3 2023.
- Funds reported $1.69B of Iovance Biotherapeutics stock for Q4 2023, up 74% quarter-over-quarter.
- 48 funds opened new Iovance Biotherapeutics positions in Q4 2023 and 36 closed out, a net change of +12 holders.
- The largest Iovance Biotherapeutics buyer in Q4 2023 was Palo Alto Investors, an estimated $11M added.
- The largest Iovance Biotherapeutics seller in Q4 2023 was Millennium Management, an estimated $36M sold.
Based on aggregated 13F filings for Q4 2023.